Theradiag SA - Asset Resilience Ratio
Theradiag SA (ALTHE) has an Asset Resilience Ratio of 15.59% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALTHE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2023)
This chart shows how Theradiag SA's Asset Resilience Ratio has changed over time. See Theradiag SA (ALTHE) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Theradiag SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Theradiag SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.80 Million | 15.59% |
| Total Liquid Assets | €1.80 Million | 15.59% |
Asset Resilience Insights
- Good Liquidity Position: Theradiag SA maintains a healthy 15.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Theradiag SA Industry Peers by Asset Resilience Ratio
Compare Theradiag SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Theradiag SA (2010–2023)
The table below shows the annual Asset Resilience Ratio data for Theradiag SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.12% | €-21.82K ≈ $-25.51K |
€18.66 Million ≈ $21.82 Million |
-0.34pp |
| 2022-12-31 | 0.22% | €31.10K ≈ $36.36K |
€13.94 Million ≈ $16.30 Million |
-0.04pp |
| 2021-12-31 | 0.26% | €31.10K ≈ $36.36K |
€11.83 Million ≈ $13.83 Million |
-0.03pp |
| 2020-12-31 | 0.29% | €31.10K ≈ $36.36K |
€10.55 Million ≈ $12.33 Million |
0.00pp |
| 2019-12-31 | 0.30% | €31.10K ≈ $36.36K |
€10.51 Million ≈ $12.29 Million |
-0.03pp |
| 2018-12-31 | 0.33% | €31.10K ≈ $36.36K |
€9.56 Million ≈ $11.18 Million |
+0.10pp |
| 2017-12-31 | 0.23% | €31.10K ≈ $36.36K |
€13.77 Million ≈ $16.10 Million |
-33.97pp |
| 2016-12-31 | 34.19% | €5.03 Million ≈ $5.88 Million |
€14.71 Million ≈ $17.20 Million |
+14.41pp |
| 2015-12-31 | 19.78% | €1.83 Million ≈ $2.14 Million |
€9.26 Million ≈ $10.82 Million |
+1.29pp |
| 2014-12-31 | 18.50% | €1.53 Million ≈ $1.79 Million |
€8.28 Million ≈ $9.69 Million |
+17.44pp |
| 2013-12-31 | 1.06% | €31.10K ≈ $36.36K |
€2.94 Million ≈ $3.44 Million |
+0.08pp |
| 2012-12-31 | 0.97% | €31.10K ≈ $36.36K |
€3.20 Million ≈ $3.74 Million |
-23.96pp |
| 2011-12-31 | 24.93% | €575.16K ≈ $672.42K |
€2.31 Million ≈ $2.70 Million |
+24.66pp |
| 2010-12-31 | 0.27% | €10.60K ≈ $12.39K |
€3.91 Million ≈ $4.57 Million |
-- |
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more